New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis.
Cairns
A P
AP
Department of Rheumatology, Musgrave Park Hospital, Belfast, Northern Ireland, UK. andrewcairns@doctors.org.uk
Duncan
M K J
MK
Hinder
A E
AE
Taggart
A J
AJ
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins / Q000009:adverse effects
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000068800:Etanercept